key: cord-0926536-jm1yddmb authors: Ashmawy, Rasha; Hamdy, Noha A.; Elhadi, Yasir Ahmed Mohammed; Alqutub, Sulafa T; Esmail, Ola Fahmy; Abdou, Marwa Shawky Mohammed; Reyad, Omar Ahmed; El-ganainy, Samar O.; Gad, Basma Khairy; Nour El-Deen, Ahmed El-Sayed; Kamal, Ahmed; ElSaieh, Haider; Elrewiny, Ehab; Shaaban, Ramy; Ghazy, Ramy Mohamed title: A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines date: 2022-04-09 journal: J Prim Care Community Health DOI: 10.1177/21501319221089255 sha: c0878dd1d7f314df1536aa95bb56143e7754a608 doc_id: 926536 cord_uid: jm1yddmb OBJECTIVE: The presented meta-analysis (MA) aims at identifying the vaccine safety and immunogenicity in published trials about SARS-CoV-2 vaccines. METHODS: All relevant publications were systematically searched and collected from different databases (Embase, Scopus, EBSCO, MEDLINE central/PubMed, Science Direct, Cochrane Central Register for Clinical Trials (CENTRAL), Clinical Trials.gov, WHO International Clinical Trials Registry Platform (ICTRP), COVID Trial, COVID Inato, Web of Science, ProQuest Thesis, ProQuest Coronavirus Database, SAGE Thesis, Google Scholar, Research Square, and Medxriv) up to January 10, 2021. The pooled vaccine safety and immunogenicity following vaccination in phase 1 and 2 vaccine clinical trials, as well as their 95% confidence intervals (CI), were estimated using the random-effects model. RESULTS: The predefined inclusion criteria were met in 22 out of 8592 articles. The proportion of anti-severe acute respiratory distress coronavirus 2 (SARS-CoV-2) antibody responses after 7 days among 72 vaccinated persons included in 1 study was 81% (95% CI: 70-89), after 14 days among 888 vaccinated persons included in 6 studies was 80% (95% CI: 58-92), after 28 days among 1589 vaccinated persons included in 6 studies was 63% (95% CI: 59-67), after 42 days among 478 vaccinated persons included in 5 studies was 93% (95% CI: 80-98), and after 56 days among 432 vaccinated persons included in 2 studies was 93% (95% CI: 83-97). Meta regression explains more than 80% of this heterogeneity, where the main predictors were; the inactivated vaccine type (β = 2.027, P = 0.0007), measurement of antibodies at week 1 (β = −4.327, P < 0.0001) and at week 3 of the first dose (β = −2.02, P = 0.0025). Furthermore, the pooled proportion adverse effects 7 days after vaccination was 0.01 (0.08-0.14) for fever, headache 0.23 (0.19-0.27), fatigue 0.10 (0.07-0.13), and 0.18 (0.14-0.23) for muscle pain. CONCLUSION: Immunogenicity following vaccination ranged from 63% to 93% depending on the time at which the antibody levels were measured. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in corona virus disease 2019 . COVID-19 pandemic emerged from Wuhan in 2019, the infection spread to more than 190 countries. According to the World Health Organization's (WHO) latest report on January 2, 2022, the disease affected a total of nearly 289 million subjects, and more than 5.4 million deaths globally. 1, 2 This zoonotic disease has rapidly crossed species to humans, thereby making it a highly contagious disease transmitted through respiratory droplets, infected surfaces, or human contacts. 3 The virus attacks not only the lower respiratory system causing viral pneumonia but also affects other systems such as the gastrointestinal, renal, hepatic, and central nervous systems leading to a wide range of symptoms and potential organ failure. 4 The only recommended preventive measures are wearing masks, social distancing, caring for personal hygiene, and avoiding overcrowded and poorly aerated area. 5, 6 The mental and economic burdens impose more pressure on the vaccine development industry to flatten the pandemic curve and regain normal life activities. [7] [8] [9] Unrevealing the viral composition indicated 4 main structural proteins, namely spike (S), nucleocapsid (N), envelope (E), and membrane (M) proteins. The most important one among the 4 proteins is the S protein, which is responsible for viral attachment, fusion, and initiated endosome-mediated host entry. 10 Subsequently, all scientific efforts to design an effective vaccine depends on using the S protein to effectively deliver the viral antigens and induce host immunological responses. 3 According to the WHO latest report on January 18, 2022, the landscape of vaccine development included 140 COVID-19 vaccine studies in the different phases of clinical development. Additionally, 194 vaccines in preclinical studies were reported. 11 Data are available on 19 inactivated virus studies, 19 non-replicating viral vector studies, 23 RNA-based vaccine, 47 protein subunit vaccines, 16 DNA-based vaccines, 4 replicating viral vector, 6 virus like particle, 2 replicating viral vector with antigen presenting cell, 2 live attenuated virus, 1 nonreplicating viral vector with antigen presenting cell, and 1 bacterial antigen-spore expression vector. Each of which is at a variable randomized controlled trial (RCT) phase compared against placebo control groups with variable risks of bias. 11 Pfizer-BioNTech, Moderna, Sputnik V, Convidecia, Johnson & Johnson, EpiVacCorona, Sinopharm, and Sinovac vaccines are approved to be employed in distinct countries, and some of them are for limited use in emergencies only. 12 In December 2020, a mass vaccination program started, and as of January 20, 2022 and 9.8 billion doses have been administered globally, thereby representing 60.3% of the whole worldwide population. 1, 2, 13 The WHO recommended the administration of COVID-19 vaccines for the high-risk population including older adults. The ideal vaccine should have a favorable safety profile and proven efficacy measured by the prevention of virologically confirmed diseases or the transmission or both and should provide at least 6-month protection. 14 One of the chief markers of immunogenicity is anti-SARS-CoV-2 antibodies, which have been reported to predict disease severity and survival. 15 Anti-SARS-CoV-2 antibodies provide efficient sterilizing immunity in vaccinated individuals. 16 A secondary vital outcome should involve a vaccine safety profile and reactogenicity. The fast-track evaluation of SARS-CoV-2 raises concerns about its full safety profile. 17, 18 Most studies have reported pain, fever, injection site pain, and fatigue; however, more long-term follow up is recommended. Some occasional serious side effects or even deaths have also been reported with selected individuals during clinical studies and the marketing phase, which necessitate an overall evaluation of the vaccines' safety. [19] [20] [21] Vaccine immunogenicity assays are performed under good clinical laboratory practices. In phase 1 and 2 vaccine studies, the standards of reporting immunogenicity data are guided by the European Medicine Agency guidelines, which include but are not limited to reporting the predetermined seroconversion rate, the change in geometric mean concentrations in the antibody titers, and the antigen-specific T-cell responses. 22 Despite the high vaccine safety indication of the available first generation COVID-19 vaccines on healthy adults, several studies have reported product-related vaccine safety issues, such as adverse events following immunization, which might be linked or not to the vaccine administration. In addition, the vaccine trials have discussed adverse events of special interest, which are general pre-specified vaccine safety issues usually known as events after vaccination. 23 Safety of COVID-19 vaccines is one of the concerns affecting the acceptance of the population to be vaccinated. Studies on vaccine hesitancy found that the refusal or delaying the vaccination was affected by the population's trust in the safety and efficacy of vaccines. 24 Therefore, the current work aims to reach elaborative evidence about vaccine immunogenicity and safety across various first-generation COVID-19 vaccines. This is to be achieved by a systematic review of the published studies with predefined inclusion criteria to include only phase 1 and 2 clinical trials on COVID-19 vaccine immunogenicity to SARS-CoV-2 and the associated product-related adverse events. Information on vaccine effectiveness is rapidly evolving and globally monitored, thus it is beyond the scope of this article. 1 and Medxriv. The search terms were determined and approved after the consultation of PubMed help. The search terms included ("Coronavirus" OR "Coronavirus infections" OR "COVID 2019" OR "SARS2" OR "SARS-CoV-2" OR "SARS-CoV-19" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus infection" OR "severe acute respiratory pneumonia outbreak" OR "novel CoV" OR "2019 ncov" OR "sars cov2" OR "cov2" OR "ncov" OR "COVID-19" OR "COVID19" OR "coronaviridae" OR ""coronavirus") AND ("Vaccin* safety" OR "Vaccin* immunogenicity"). Manual search was performed by tracking citations, references, and related articles for these eligible papers. 28 The database search ended on January 10, 2021. Inclusion criteria: We included studies reporting COVID-19 immunogenicity or safety, which were published since 2019 with no language restriction. Thus, we included all studies with various COVID-19 vaccine types, doses, delivery, designs, mode of action, and different comparator groups (placebo, another vaccine, and distinct doses of the same vaccine). Moreover, we included studies reporting any gender of healthy adult populations (age above 18 years old). The inclusion criteria also incorporated no previous SARS-CoV-2 infection, no previous history of seizures, no febrile illness at the time of vaccination, participants who did not receive any blood products for the last 4 months, or no history of allergic reactions to any of the vaccine ingredients, and all types of clinical trials phases 1 and 2 only. Further, we excluded the abstract-only papers, research proposals, conference, editorial, author responses, all reviews, case reports, case series, books, and studies with data not accurately reliably extracted, duplicate, or overlapping data. We mainly focused on the vaccine immunogenicity as our primary outcome. COVID-19 vaccine immunogenicity is defined as the ability of a vaccine to induce an immune response (antibody-and/or cell-mediated immunity) in a vaccinated individual. 25 Anti-SARS-CoV-2 antibodies were accessed at the baseline and at different periods of time according to each study. Our secondary outcome was the vaccine safety, which was assessed by reporting any adverse events within 7 days after the vaccination or during other periods of time according to each vaccine type. The adverse events could be local or systemic, and the reported adverse effects varied between pain at the local injection site, rash, fever, chills, fatigue, muscle pain, hospitalization, mechanical ventilation, and death. All the citations were imported into Endnote 18 to detect and remove the duplicates with 2 methods: title, author, year, and journal. Abstract screening, followed by full text screening phases, was started with articles extracted into an Excel sheet with the author's name, publication year, journal, DOI, URL link, and abstract. The screening was performed independently by BK, NH, AK, MS, RS, SA, OR, AN, EE, YE, SG, and MB. The third part (HS, RA, OF) solved the disagreement between the reviewers. Additionally, the articles were extracted in an Excel sheet with the following predefined data: year of publication, author name, country, study design, inclusion, and exclusion criteria, reported immunogenicity, and reported adverse drug reactions. Full text eligibility was conducted by BK, NH, AK, MS, RS, SA, OR, AN, EE, YE, SG, and MB, and disagreement was solved by HS, RA, and OF. The Excel sheets were available online for reviewers through this link. The agreement between reviewers was tested by the kappa Fleiss test, k 0.86. Measures of treatment effects: We calculated the pooled proportion with respective 95% confidence intervals (CIs) and performed the forest plots to show individual studies and pooled estimates. Cochrane Q and I² tests were utilized to assess and measure the heterogeneity between the studies, considering that I 2 ≥ 75% represents substantial heterogeneity and that the strength of evidence for heterogeneity is P ≤ 0.05 from the Q test according to the Cochrane Handbook for Systematic Reviews of Interventions. 26 In the case of substantial heterogeneity, the DerSimonian and Laird random-effects models were applied to pool the outcomes; otherwise, a fixed-effect model was used. The subgroup analysis and outlier removal were employed to resolve the heterogeneity. Metaregression was conducted to explain the significant predictors of remaining heterogeneity considering the type of used vaccine, weeks of antibodies measurement after first dose and the country. The publication bias was assessed for our primary outcome (anti-SARS-CoV-2 antibodies after 28 days) by visual inspection of the funnel plot and statistically by the Begg's modified funnel plot as presented in Figure 1 . Figure 2 depicts the flow diagram of the selection process. From a total of 8592 potentially relevant articles, 1356 duplicate articles were excluded by Endnote, and 1676 articles were excluded as they had been published before 2019. A total of 5560 articles were eligible for title abstract screening, and only 32 articles were eligible for full text screening after removing irrelevant (5190) and duplicate articles (338). In total, 17 articles were included for quantitative assessments after full text screening, and another 5 articles were added manually. Hence, 22 articles were included. The types of investigated studies encompassed doubleblinded, [29] [30] [31] [32] [33] [34] [35] [36] single-blinded, 18, [37] [38] [39] [40] [41] [42] [43] or non-randomized, [44] [45] [46] some of them were open label. [47] [48] [49] They also included phase 1, 29, 30, 32, 42, 43, [46] [47] [48] [49] phase 2, 18,29,36 phase 1/2, [33] [34] [35] [37] [38] [39] [40] [41] 44, 45 or phase 1/2a 31 randomized controlled trials. The age of most of the included subjects ranged from 18 to 60 years, except for some studies including older ages reaching 70, 18 80, 34 and 85 years. 42, 43 Male and female genders were equally distributed in the studies, except for the study of Ella et al., 29 who included more male sex in their work. In addition, The types of vaccines investigated involved vectored, 18, 31, [36] [37] [38] [39] 44, 46 inactivated virus, 29, 30, [33] [34] [35] 40 and mRNA vaccines. [41] [42] [43] 45, 47, 48 The trial durations ranged from 2 weeks 36 to more than 3 months. 43 The chief outcomes investigated in the clinical trials were vaccine immunogenicity, safety, and tolerability of distinct vaccines. Immunogenicity was determined via serological markers, such as measuring antibody titers, 34, 36, 37, 39, 46, 47 geometric mean titers, 41, 47 specific IgG responses, 18, 29, 32, 35, 38, [40] [41] [42] [43] 45, 49 and T-cell responses, 35, 36, [46] [47] [48] which included a strong CD4 cytokine response involving type 1 helper T-cells 47 while Zhang et al. 35 did not assess the T-cell responses in the phase 2 trial. The adverse effects including, local, systemic, and unsolicited ones were examined at time points between day 7 until day 28, 30, 31, 36, 44 and sometimes up to 8 weeks postdose. 38, 40, 49 Most of the reported vaccines were well tolerated with high reactogenicity 39 ; however, sometimes requiring booster doses (Tables 1-3 ). 37 The pooled proportion of anti-SARS-CoV-2 antibody response (AR) for COVID-19 vaccines after 28 days was 63% (95% CI: 59-67) among 1589 vaccinated individuals included in 6 studies (I 2 = 98%, P ≤ 0.01) as presented in Figure 3 . We performed a subgroup analysis based on the type of COVID-19 vaccines to investigate such significant heterogeneity. The pooled prevalence of AR for adenovirus vector vaccines was 56% (95% CI: 51-60, P ≤ 0.5) among 490 vaccinated individuals included in 2 studies (I 2 = 0%). While non-adenovirus vectored vaccines exhibited higher immunogenicity, AR was 90% (95% CI: 86-93, P ≤ 0.02) among 1099 vaccinated individuals included in 4 studies (I 2 = 71%). Figure 3 illustrates that the test for subgroup differences indicated that immunogenicity was significantly affected by the type of COVID-19 vaccines (P ≤ 0.05). The pooled proportion of anti-SARS-CoV-2 antibody responses for COVID-19 vaccines after 7 days could not be calculated because only 1 paper studied the neutralizing antibodies response after 7 days. Among 72 vaccinated persons, 81% developed neutralizing antibodies in 7 days (95% CI: 70-89). See Supplemental Figure S1 . The pooled proportion of anti-SARS-CoV-2 antibody responses for COVID-19 vaccines after 14 days among 888 vaccinated persons included in 6 studies was 80% (95% CI: 58-92) with high heterogeneity (I 2 = 97%), P < 0.01. See Supplemental Figure S1 . To identify the cause of this substantial heterogeneity, we conducted a subgroup analysis. The type of vaccine was employed for subgrouping, and the vaccines were sub-grouped into either adenovirus vectored vaccines or non-adenovirus vectored vaccines. The pooled prevalence of anti-SARS-CoV-2 antibody responses for adenovirus vectored COVID-19 vaccines after 14 days among 184 vaccinated persons included in 2 studies was 42% (95% CI: 26-60) (I 2 = 83%), P = 0.02. The pooled prevalence of anti-SARS-CoV-2 antibody responses for non-adenovirus vectored COVID-19 vaccines after 14 days among 704 vaccinated persons included in 4 studies was 91% (95% CI: 75-97) (I 2 = 95%) P < 0.01. The pooled proportion of anti-SARS-CoV-2 antibodies responses for COVID-19 vaccines after 42 days among 478 vaccinated persons included in 5 studies was 93% (95% CI: 80-98) (I 2 = 84%), P < 0.01. See Supplemental Figure S1 . We conducted subgroup analysis based on the type of vaccine, where vaccines were sub-grouped into either mRNA vaccines or non-mRNA vaccines, to identify the cause of such substantial heterogeneity. The pooled prevalence of anti-SARS-CoV-2 antibody responses for mRNA COVID-19 vaccines after 42 days among 158 vaccinated persons included in 3 studies was 94% (95% CI: 74-99) (I 2 = 78%), P = 0.01. The pooled prevalence of anti-SARS-CoV-2 antibody responses for non-mRNA COVID-19 vaccines after 42 days among 320 vaccinated persons included in 2 studies was 96% (95% CI: 25-100) (I 2 = 90%) P < 0.01. The pooled prevalence of anti-SARS-CoV-2 antibody responses for COVID-19 vaccines after 56 days among 432 vaccinated people included in 2 studies was 93% (95% CI: 83-97) (I 2 = 80%), P = 0.03. See Supplemental Figure S1 . We found substantial heterogeneity when we tried to combine all the reported anti-SARS-CoV-2 antibody studies (I 2 = 98%). Thus, we conducted a meta regression model to explain the reason for this considerable heterogeneity. The main predictors of heterogeneity are the type of vaccine used and the time of anti-SARS-CoV-2 antibody measurement after the first dose of vaccine, and this model can explain Total n = 76and n = 38 in each study. Phase1 (rAd26-S) n = 9, (rAd5-S) n = 9 Phase2 (rAd26-S) n = 9, (rAd5-S) n = 20. The pooled proportion of fever among inactivated COVID-19 vaccine receivers after 7 days among 2533 vaccinated persons included in 14 studies was 10% (95% CI: 8-14) (I 2 = 95%), P < 0.01 after the outlier removal. See Figure 4 . The pooled proportion of headache among COVID-19 vaccine receivers after 7 days among 2616 vaccinated persons included in 10 studies was 23% (95% CI: 19-27) (I 2 = 97%), P < 0.01. See Figure 5 . Subgroup analysis was performed to resolve the heterogeneity by the types of vaccines employed. The highest proportion was observed among individuals who received the adenovirus vectored and virus like particles vaccines (34%). The good safety profile for heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has induced strong cellular and humoral immune response in 100% of the volunteers. Ramasamy et al 18 [AstraZenca] UK Efficacy (symptomatic cases, confirmed virology testing). Safety (adverse events) Reactogenicity, and immunogenicity, efficacy against severe and non-severe COVID-19, death, and seroconversion Safe and well-tolerated with a lower reactogenicity profile in older adults than in younger adults. Similar immunogenicity across age groups after booster vaccination. Tebas et al 49 Mild to moderate adverse effect. Higher doses yielded higher values of binding and neutralizing antibodies. Conduction of Phase3 is expected to conclude better outcomes. Sadoff et al 31 pre-print medRxiv [Johnson and Johnson] Belgium and USA safety, reactogenicity, and immunogenicity Vaccine candidate Ad26.COV2.S has an acceptable safety and reactogenicity profile and is immunogenic at both titers. The vaccine candidate is less reactogenic in older adults, increases with the higher dose. S-binding Ab titers increased from baseline to Day 29 post-vaccination in 99% of the participants in cohort 1a and 100% of the first participants in cohort 3. Concurrent production of neutralizing antibodies was observed, in addition to activation of virus-specific CD4+ and CD8 + T cells, and robust release of immunemodulatory cytokines such as IFNγ, which represents a coordinated immune response to counter a viral intrusion. Jackson et al 48 No severe adverse reactions (redness, itching, and swelling at the inoculation site) and few cases of slight fatigue. The immune functions were upregulated in comparison with the placebo group. The pooled proportion of fatigue among COVID-19 vaccine receivers after 7 days among 32 678 vaccinated persons included in 10 studies was 10% (95% CI: 7-13) (I 2 = 99%), P < 0.01. See Figure 6 . Subgroup analysis was performed to resolve the heterogeneity by the type of vaccine utilized, and 56% was the proportion among the mRNA vaccinated participants, which was the highest proportion. See Figure 6 . The pooled proportion of muscle pain among Adenovirus vectored COVID-19 vaccine recipients after 7 days among 3237 vaccinated persons included in 9 studies was 18% (95% CI: 14-23) with heterogeneity (I 2 = 96%), P = 0.57. See Figure 7 . While in mRNA vaccine, the pooled prevalence of muscle pain among COVID-19 vaccine recipients after 7 days included in 2 studies was 17% (95% CI: 12-23) (I 2 = 0%), P = 0.92. See Figure 7 . This study provides empirical evidence for the safety and immunogenicity of COVID-19 vaccines, and this is crucial as demonstrating the safety and benefits of COVID-19 vaccines is critical to enhance public trust in COVID-19 vaccination, particularly in countries with high rates of vaccine hesitancy. 24, 50 Moreover, results from this analysis will provide information about the number of days required for the development of anti-SARS-CoV-2 antibodies developed from the sequential immunization strategy. Information on the duration of the development of the commonly reported vaccine adverse effects across various vaccine technology platforms. Some of the criteria considered to develop new vaccines are animal immunogenicity, toxicity data, immunogenicity response in adults, possible impact on public health, chances of acceptance by the community, cost-effectiveness, and the preexistence of a vaccine with a satisfactory risk-benefit profile. The immune response primarily measured during the early stages of vaccine development (phase 1/2) should evaluate the following: amount, class, subclass, and function of each specific antibody. 22 Phase 1 aims to evaluate vaccine safety, reactogenicity, and the collection of immune responses. Generally, the dose, immunization schedule, and mode of vaccine administration are also assessed, while the objective of phase 2 is to identify the vaccine preparation, optimal dose, and schedule. 51 This MA includes 22 studies; 7 were conducted in China, 30,33-36,43,46 5 in the USA, 41,42,47-49 4 in the UK, 18,37-39 1 in India, 29 1 in Germany, 45 1 in Australia, 40 1 in Canada, 32 1 in Russia, 44 and 1 in Belgium and the USA. 31 The sample size varies from 39 participants 49 who received the vaccination to 1077. 39 The types of vaccines administered were different, and different doses were used. The duration of the study varies from 11 days 46 in China to 194 days 29 in India. Age limitations of the studied population in each study were variable. No participant below 16 years old was included in any study, and randomization was performed in 19 studies. The I 2 statistics values have shown a substantial heterogeneity in Figure 3 , which can be attributed to variability in gender and age. Various studies have validated that age and sex are the determinants of different immune responses, especially to viral vaccines, which may vary between males and females in some of the immunogenic parameters, such as humoral responses and cell-mediated immunity. None of the MA studies have included participants below 16 years of age. For the immune responses of older individuals, it has been interpreted as with previous multiple exposures to diseases, and the elderly were more likely to show a high diversity of immune responses to viruses more than what is observed among the younger population. [52] [53] [54] Regarding vaccine development platforms and formulation, our review included 8 studies on replication-defective adenovirus vector vaccines, 6 studies on mRNA vaccines, 1 study on synthetic peptide/virus-like particle vaccines, 1 on DNA-based vaccines, and 6 studies on inactivated vaccines as shown in Table 2 . Most of the included studies reported immunogenic responses on the 28th day post-vaccination. A similar number of studies reported immunogenic responses at day 42 post-vaccination. 30, 32, 34, 35, [37] [38] [39] [40] [41] [42] [43] 45, [47] [48] [49] The shortest reported duration of immunogenic responses was at day seven post-vaccination, which was observed in 1 study. 30 The proportion of anti-SARS-CoV-2 antibody responses for COVID-19 vaccines after 7 days among 72 vaccinated persons was 81%, and the proportion of anti-SARS-CoV-2 antibody responses for COVID-19 vaccines after 14 days among 888 vaccinated persons was 80%. Furthermore, the proportion of anti-SARS-CoV-2 antibody responses for COVID-19 vaccines after 28 days among 1589 vaccinated persons included in 6 studies was 63%. After 42 days, the proportion of anti-SARS-CoV-2 antibody responses for COVID-19 vaccines among 478 vaccinated persons included in 5 studies was 93%, and the proportion of anti-SARS-CoV-2 antibody responses for COVID-19 vaccines after 56 days among 432 vaccinated persons included in 3 studies was 93%. The observed escalation in the proportion of anti-SARS-CoV-2 antibodies supports the role of a sequential immunization strategy in producing high levels of anti-SARS-CoV-2 antibodies, especially among mRNA vaccine recipient groups. Nonetheless, He et al 55 verified that the immune response was not strong with the inactivated vaccine nor with adenovirus vaccine recipients. Even though the WHO International Standard for anti-SARS-CoV-2 immunoglobulin with a unit of 250 IU/ampoule, is available (anti-SARS-CoV-2 antibody activity). Anti-SARS-CoV-2 immunoglobulin units have yet to be assigned by the first WHO International Reference Panel. As a result, there is a knowledge gap in determining the immune response cut-off points in various phases 1 and 2 randomized controlled trial (RCT), and vaccine trials. Within the included studies, we assessed the following adverse effects: fever, headache, fatigue, and muscle pain. The findings presented the proportion of fever 7 days after the vaccine administration at 10%, and this was reported in 3% and 13% in inactivated and adenovirus vectored or virus-like particle vaccine recipients, respectively. This relatively low adverse event is supported by the findings reported by Logunov et al 56 phase 3 RCT about the safety of adenovirus (rAd)-based COVID-19 vaccine, which includes flu-like illness, reaction at the site of injection, headache, and fatigue. After 7 days, fatigue incidence was 10% and is mostly reported among mRNA vaccine recipients. Findings are consistent with the review conducted by Kaur et al 57 in March 2021, who reported about the mRNA vaccine adverse reactions that included mild to moderate intensity effects, such as headache, chills, fatigue, myalgia, and pain at the site of injection. Local adverse reactions were mostly pain at the site of injection. The proportion of headache 7 days after the vaccine administration was at 23% and mostly caused by adenovirus vectored vaccine. Headache was found to be a common presentation after all forms of COVID19 vaccine administration. 56, 57 Our findings affirmed that 7 days post-vaccination, muscle pain prevalence was slightly higher among adenovirus vectored vaccine recipients than mRNA vaccinated individuals at 21% and 17%, respectively. Our MA findings exhibited relatively high statistical heterogeneity in fatigue at various types of vaccines studies as presented in Figure 1 . Finally, the highest observed heterogeneity can be related to the publication bias in which non-statistically significant results are usually not published. Our MA was unable to provide a definitive conclusion on vaccine efficacy as most of the included studies were phase 1 and 2 novel vaccine studies. Additionally, the immunogenicity against the variant strains of SARS-Cov-2 was not assessed in this study. Figure 2 depicts that a robust criterion followed in identifying and including the relevant articles to answer the PICO; however, this MA has limitations. The included phase 1 and phase 2 studies are lacking the control arms. Moreover, the short duration of the reported immunogenicity within some of the included studies makes the analysis subjected to latency bias. 58 Given that non-statistically significant results are usually not published, the publication bias may impact the current analysis.Nevertheless, the results from this review will provide information on the days required for the development of the anti-SARS-CoV-2 antibodies developed from the sequential immunization strategy. Moreover, it provides information on the duration of the development of the commonly reported vaccine adverse effects across various vaccine technology platforms. More communitybased vaccine efficacy studies on COVID-19 are essential to articulate the relative risk reduction across various COVID-19 vaccines. 59 The development of second generation COVID-19 vaccines is critical to address the issues of viral mutations. 55 The immunogenicity, following phase 1 and 2 novel vaccine studies, ranged from 63% to 93% depending on the time at which antibodies level was measured. The safety and immunogenicity data from this MA will provide information on the days required for the development of anti-SARS-CoV-2 antibodies developed from the sequential immunization strategy. The adverse events were mostly mild and appeared to be well tolerated. The safety and immunogenicity data, from the phase 1 and 2 trials, needs to further ascertain its safety and protection efficacy against COVID-19. Landscape of observational study designs on the effectiveness of COVID-19 vaccination World Health Organization COVID-19 weekly epidemiological update. 2021. Accessed COVID-19 vaccine: a comprehensive status report Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases Centers for Disease Control and Prevention Letter from Egypt Economic consequences of Covid-19: a counterfactual multicountry analysis. Center for Economic and Policy Research Sleep quality and anxiety among Egyptian population during covid-19 pandemic The outbreak of COVID-19 coronavirus and its impact on global mental health Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation World Health Organization COVID-19 vaccine tracker and landscape. 2022. Accessed Statistics and research: coronavirus (COVID-19) vaccinations World Health Organization [WHO]. WHO Target Product Profiles for COVID-19 Vaccines. World Health Organization COVID-19-neutralizing antibodies predict disease severity and survival SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates COVID-19 vaccines: where we stand and challenges ahead Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a primeboost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots The clinical development process for a novel preventive vaccine: an overview World Health Organization. WHO R&D Blueprint COVID-19 Vaccines: Knowledge Gaps and Research Priorities WHO Ad Hoc Consultation. WHO; s2021 The coronavirus disease 2019 (COVID-19) vaccination psychological antecedent assessment using the Arabic 5c validated tool: an online survey in 13 Arab countries COVID-19 vaccine effectiveness research. 2021. Accessed Cochrane Handbook for Systematic Reviews of Interventions Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement A step by step guide for conducting a systematic review and meta-analysis with simulation data Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-corv: a randomised, double-blind, placebo-controlled, phase 1/2 trial Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults Safety and immunogenicity of two RNA-based covid-19 vaccine candidates First report demonstrating the safety and immunogenicity of the SARS-COV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, observer-blind Phase I study Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults An mRNA vaccine against SARS-CoV-2-preliminary report Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial Enhancing Public Trust in COVID-19 Vaccination: The Role of Governments Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization technical consultation Sex differences in vaccine-induced humoral immunity The Xs and Y of immune responses to viral vaccines Variability in the immune system: of vaccine responses and immune states COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Adverse events reported from covid-19 vaccine trials: a systematic review Clinical Epidemiology. Practice & Methods Preventive Medicine and Public Health We would like to thank Mrs Syeda Samia Bukhari, University of Jeddah, Saudi Arabia and EKB English language editing services for their kind review of the final version of the manuscript. RA: title and abstract reviewing, full text screening, data extraction, quality assessment, writing methodology. OR: Database search, title and abstract screening, full text screening, data extraction revision, analysis of the outcomes and writing results and part of the discussion. NH: introduction, data extraction and literature search, collection of summary table, revising the manuscript and corresponding author. MA: database search, abstract and title screening, literature search, data extraction, quality assessment. YM: database search, title and abstract screening, data extraction, collection of common outcomes. SA: Introduction, literature search, data extraction, summary table, discussion. SE: data extraction, introduction, collection of common outcomes. OE: title and abstract reviewing, text screening (data extraction), quality assessment, methodology. G: summary of outcomes, database search, follow chart of the study, literature search, title and abstract screening, full text screening, data extraction, quality assessment. AN: methodology, abstract, data extraction, collection of common outcomes. AK: database search, title and abstract screening, data extraction, collection of common outcomes. HE: responsible for the data bases collection, confirming the eligible studies and part of the analysis. EE: Database search, abstract and full paper screening, data extraction and writing the manuscript. RS: database search, title and abstract screening, data extraction. RMG: conceptualization of research idea, data base search, statistical analysis, writing manuscript. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) received no financial support for the research, authorship, and/or publication of this article. Supplemental material for this article is available online.